| Date | Time | Source | Headline | Symbol | Company |
| 11/24/2021 | 10:39AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 11/22/2021 | 9:00AM | Business Wire | The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff’s Office, to Become First in the Nation to Deploy AditxtScore™ for Immune Scoring for its Employees and First Responders | NASDAQ:ADTX | Aditxt Inc |
| 11/12/2021 | 12:00PM | Business Wire | Aditxt Webinar at 2pm ET to Explore PRESECO Results | NASDAQ:ADTX | Aditxt Inc |
| 11/12/2021 | 8:45AM | Business Wire | Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC | NASDAQ:ADTX | Aditxt Inc |
| 11/03/2021 | 9:00AM | Business Wire | Aditxt Partners With CLX Health to Offer AditxtScore™ for COVID-19 Immune Monitoring Service Through CLX’s TrustAssure™ Platform | NASDAQ:ADTX | Aditxt Inc |
| 10/20/2021 | 5:31PM | Business Wire | Aditxt Announces Closing of $4.25 Million Public Offering | NASDAQ:ADTX | Aditxt Inc |
| 10/20/2021 | 5:21PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 10/20/2021 | 12:30PM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:ADTX | Aditxt Inc |
| 10/20/2021 | 8:00AM | Business Wire | Aditxt to Present at the Dawson James 6th Annual Small Cap Growth Conference in Florida on October 21, 2021 | NASDAQ:ADTX | Aditxt Inc |
| 10/18/2021 | 7:38AM | Business Wire | Aditxt Announces Pricing of $4.25 Million Public Offering | NASDAQ:ADTX | Aditxt Inc |
| 10/12/2021 | 4:28PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:ADTX | Aditxt Inc |
| 10/12/2021 | 4:24PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 10/08/2021 | 5:17PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 10/07/2021 | 9:15AM | Business Wire | Aditxt to Present at the LD Micro Main Event in Los Angeles on October 13, 2021 | NASDAQ:ADTX | Aditxt Inc |
| 10/05/2021 | 12:42PM | PR Newswire (US) | AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since The Outbreak. | NASDAQ:ADTX | Aditxt Inc |
| 10/05/2021 | 8:45AM | Business Wire | Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Canada | NASDAQ:ADTX | Aditxt Inc |
| 10/01/2021 | 7:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ADTX | Aditxt Inc |
| 10/01/2021 | 7:04PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ADTX | Aditxt Inc |
| 10/01/2021 | 7:03PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ADTX | Aditxt Inc |
| 09/27/2021 | 8:45AM | Business Wire | Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization | NASDAQ:ADTX | Aditxt Inc |
| 09/09/2021 | 8:26AM | Business Wire | Aditxt, Inc. and SphereDX Launch AditxtScore™ for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots | NASDAQ:ADTX | Aditxt Inc |
| 09/07/2021 | 9:15AM | Business Wire | Aditxt Announces Closing of $11 Million Registered Direct Offering, and Funding of Bridge Loan Satisfying a Key Term of its Letter of Intent for Planned Acquisition of Commercial Stage Pharma Company with Anti-Viral COVID-19 Therapy | NASDAQ:ADTX | Aditxt Inc |
| 09/03/2021 | 4:13PM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) | NASDAQ:ADTX | Aditxt Inc |
| 09/03/2021 | 9:01AM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ADTX | Aditxt Inc |
| 08/30/2021 | 5:07PM | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:ADTX | Aditxt Inc |
| 08/30/2021 | 9:17AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ADTX | Aditxt Inc |
| 08/26/2021 | 9:15AM | Business Wire | Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
| 08/25/2021 | 9:16AM | Business Wire | Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19 | NASDAQ:ADTX | Aditxt Inc |
| 08/12/2021 | 5:22PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ADTX | Aditxt Inc |
| 08/11/2021 | 8:00AM | Business Wire | Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic | NASDAQ:ADTX | Aditxt Inc |